Korean Pharma Voluntarily Withdraws Phase 2 Clinical Trial Application for Elderly Sarcopenia Patients
[Asia Economy Reporter Oh Ju-yeon] Korea Pharma announced on the 10th that it has voluntarily withdrawn its application for a multicenter, dose-finding, Phase 2 clinical trial plan to evaluate the efficacy and safety of repeated administration of KP203 in elderly patients with sarcopenia.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- Instead of a National Assembly Profile, Now a 'Carpenter'... Ryu Hojung Says "I Couldn't Do a Body Profile Shoot Twice"
The company stated the reason for the voluntary withdrawal as follows: "We judged that the time required to conduct tests and prepare materials to submit supplementary data requested by the Ministry of Food and Drug Safety is excessive, making it difficult to submit the supplementary data within the deadline."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
